Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Budget alignment ensures every dollar spent serves your priorities, keeping resources directed toward meaningful gains.
21,186 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Among the market’s biggest names, only a few of the so-called magnficent seven look like buys today. This piece digs ...
A rising wave of spoof calls impersonating bank staff and law enforcement is draining customer accounts. Authorities ...
Rem’s Mortgage REIT Portfolio surged 19% over the past year as the Fed signaled a slower stance on rates, lifting inc...
Zillow reports a strong start to 2026 with rising revenue and a bold pre-marketing push. The Zillow Preview program d...
As housing markets shift, investors wonder if Opendoor can deliver a meaningful stock reaction by 2026. This guide br...
Many investors chase headline names, but a quiet stock nobody's talking about could surge as AI, data, and systems de...
Buffett’s moves often spark debates about dividend stocks. This article digs into the idea behind 'warren buffett own...
As investors eye small-cap medical devices, Inogen's INGN 2026 earnings story matters. This analysis breaks down Q1 r...
Alpha (AMR) just reported Q1 2026 results, raising questions about growth and margins. This analysis breaks down the ...
The POWI 2026 earnings transcript sheds light on how the company performed in Q1 and what the path ahead could look l...
Three EV peers face a common challenge: turn bold promises into durable profits. This guide compares Tesla, Rivian, a...